Cooperative interaction between mutant p53 and des(1-3)IGF-I accelerates mammary tumorigenesis

被引:71
作者
Hadsell, DL
Murphy, KL
Bonnette, SG
Reece, N
Laucirica, R
Rosen, JM
机构
[1] Baylor Coll Med, Dept Pediat, USDA ARS, Childrens Nutr Res Ctr, Houston, TX 77030 USA
[2] Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA
[3] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA
关键词
transgenic mouse model; IGF-I; apoptosis; mutant p53; tumorigenesis;
D O I
10.1038/sj.onc.1203386
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mammary tumorigenesis was analysed in transgenic mice which overexpress des(1-3)hIGF-I (WAP-DES) and/or a mutant form of p53 (p53(172R-H)). Nonlactating, multiparous WAP-DES mice exhibited hyperplastic lesions termed mammary interepithelial neoplasia (MIN) which constitutively expressed WAP-DES, By 23 months of age, 53% of the WAP-DES mice developed mammary adenocarcinomas. A 75% reduction in both apoptosis and proliferation was observed in the normal mammary glands of WAP-DES mice, Mammary tumor incidence in WAP-DES/p53 bitransgenic mice was similar to that of WAP-DES and 2-3-fold greater than that of nontransgenic and p53(172R-H) females, Tumor latency, however, was reduced by 8 months in bitransgenic mice as compared to mice of the other three genotypes. Aneuploidy was frequently observed in tumors from bitransgenic and p53(172R-H) mice, but not from mice expressing only the WAP-DES transgene, Expression of IGFBP3 was elevated in tumors from WAP-DES, but not bitransgenic mice, indicating an alteration in the p53/IGF-I axis. These studies indicate that overexpression of des(1-3)hIGF-I increases the frequency of MIN and stochastic mammary tumors and that the appearance of tumors displaying genomic instability is accelerated by mutant p53(172R-H).
引用
收藏
页码:889 / 898
页数:10
相关论文
共 50 条
  • [11] CULLEN KJ, 1990, CANCER RES, V50, P48
  • [12] GAIN OF FUNCTION MUTATIONS IN P53
    DITTMER, D
    PATI, S
    ZAMBETTI, G
    CHU, S
    TERESKY, AK
    MOORE, M
    FINLAY, C
    LEVINE, AJ
    [J]. NATURE GENETICS, 1993, 4 (01) : 42 - 46
  • [13] DUNN TB, 1959, PHYSIOPATHOLOGY CANC, P38
  • [14] Abnormal centrosome amplification in the absence of p53
    Fukasawa, K
    Choi, T
    Kuriyama, R
    Rulong, S
    VandeVoude, GF
    [J]. SCIENCE, 1996, 271 (5256) : 1744 - 1747
  • [15] Gai X X, 1988, Oncogene Res, V3, P377
  • [16] Insulin-like growth factor-binding protein (IGFBP-3) predisposes breast cancer cells to programmed cell death in a non-IGF-dependent manner
    Gill, ZP
    Perks, CM
    Newcomb, PV
    Holly, JMP
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (41) : 25602 - 25607
  • [17] An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control
    Gualberto, A
    Aldape, K
    Kozakiewicz, K
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (09) : 5166 - 5171
  • [18] HACHIYA M, 1994, ANTICANCER RES, V14, P1853
  • [19] Targeted expression of des(1-3) human insulin-like growth factor I in transgenic mice influences mammary gland development and IGF-Binding protein expression
    Hadsell, DL
    Greenberg, NM
    Fligger, JM
    Baumrucker, CR
    Rosen, JM
    [J]. ENDOCRINOLOGY, 1996, 137 (01) : 321 - 330
  • [20] Database of p53 gene somatic mutations in human tumors and cell lines: Updated compilation and future prospects
    Hainaut, P
    Soussi, T
    Shomer, B
    Hollstein, M
    Greenblatt, M
    Hovig, E
    Harris, CC
    Montesano, R
    [J]. NUCLEIC ACIDS RESEARCH, 1997, 25 (01) : 151 - 157